Comparative Pharmacology
Head-to-head clinical analysis: AMICAR versus AMINOCAPROIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMICAR versus AMINOCAPROIC ACID.
AMICAR vs AMINOCAPROIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by blocking the binding of plasminogen to fibrin.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by binding to plasminogen and blocking its conversion to plasmin.
4-5 g IV loading dose over 1 hour, followed by 1 g/hour IV continuous infusion for 8 hours or until bleeding controlled; oral: 5 g PO initially, then 1-1.25 g PO every hour as needed.
Loading dose: 4-5 g intravenously (IV) over 1 hour, followed by continuous IV infusion of 1 g/hour for 8 hours or until bleeding controlled. Oral: 1 g every hour for 8 hours, then 1 g every 2 hours for 8 additional hours.
None Documented
None Documented
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal elimination half-life: 2 hours (range 1-3.5 hours). After high doses or renal impairment, half-life may prolong (up to 5-10 hours).
Terminal elimination half-life is approximately 2 hours (range 1-3 hours) in patients with normal renal function. Prolonged in renal impairment (up to 20 hours in anuria).
Renal: >99% of absorbed dose excreted unchanged in urine. Biliary/fecal: negligible (<1%).
Primarily renal (80-90% unchanged). A small fraction (<5%) is excreted as metabolites. No significant biliary/fecal elimination.
Category C
Category C
Antifibrinolytic
Antifibrinolytic